Comparing Revenue Performance: Alnylam Pharmaceuticals, Inc. or Bausch Health Companies Inc.?

Alnylam's Revenue Soars, Bausch Health Steady

__timestampAlnylam Pharmaceuticals, Inc.Bausch Health Companies Inc.
Wednesday, January 1, 2014505610008263500000
Thursday, January 1, 20154109700010498800000
Friday, January 1, 2016471590009674000000
Sunday, January 1, 2017899120008724000000
Monday, January 1, 2018749080008380000000
Tuesday, January 1, 20192197500008601000000
Wednesday, January 1, 20204928530008027000000
Friday, January 1, 20218442870008434000000
Saturday, January 1, 202210374180008124000000
Sunday, January 1, 202318282920008757000000
Monday, January 1, 20242248243000
Loading chart...

Unleashing insights

Revenue Growth: Alnylam Pharmaceuticals vs. Bausch Health

In the dynamic world of pharmaceuticals, revenue performance is a key indicator of a company's market position and growth potential. Alnylam Pharmaceuticals, Inc. and Bausch Health Companies Inc. have shown contrasting revenue trajectories over the past decade. From 2014 to 2023, Alnylam's revenue skyrocketed by approximately 3,500%, starting from a modest $50 million to an impressive $1.8 billion. This growth reflects Alnylam's successful innovation and market expansion strategies.

Conversely, Bausch Health's revenue has remained relatively stable, fluctuating around the $8 billion mark. Despite a slight dip in 2020, Bausch Health has maintained a strong revenue base, showcasing its resilience in a competitive market. This comparison highlights Alnylam's rapid ascent in the pharmaceutical industry, while Bausch Health continues to leverage its established market presence.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025